Distribution of Phase I lung cancer trials may be consolidating at top-performing US sites

Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest-volume clinical trial sites largely located in major cities, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22.